RECURRENT NEUROBLASTOMA

This early-stage trial is testing a new type of cell therapy for children and young adults whose neuroblastoma or osteosarcoma has returned or not responded to standard treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to recognize a specific p…

This study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This early-phase study aimed to test the safety and effectiveness of a two-drug immunotherapy combination (nivolumab and ipilimumab) in children, teens, and young adults. It was specifically for patients whose cancers had returned or stopped responding to standard treatments and …

This study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…

This study is for children whose high-risk neuroblastoma has come back or hasn't responded to initial treatment. It tests whether adding a drug called eflornithine (DFMO) to a standard combination of chemotherapy and immunotherapy works better. The goal is to see if the new combi…

This study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…

This early-stage study is testing a combination of three drugs—lenalidomide, dinutuximab, and isotretinoin—in children and young adults whose neuroblastoma has returned or hasn't responded to standard treatments. The main goal is to find the safest dose of lenalidomide when given…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …

This study aims to understand the long-term health problems that can occur in people who survived high-risk neuroblastoma as children. Researchers are following 376 survivors who were diagnosed after the year 2000 and finished their main cancer treatments at least two years ago. …